AI assistant
Avidity Biosciences, Inc. — Director's Dealing 2022
Aug 27, 2022
30894_dirs_2022-08-26_9d8eb071-0759-488e-b456-48804ef04f56.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Avidity Biosciences, Inc. (RNA)
CIK: 0001599901
Period of Report: 2022-08-24
Reporting Person: Boyce Sarah (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-08-24 | Common Stock | M | 35045 | $1.24 | Acquired | 35045 | Direct |
| 2022-08-24 | Common Stock | S | 35045 | $22.7971 | Disposed | 0 | Direct |
| 2022-08-25 | Common Stock | M | 14855 | $1.24 | Acquired | 14855 | Direct |
| 2022-08-25 | Common Stock | S | 14855 | $23.069 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-08-24 | Stock Option (Right to Buy) | $1.24 | M | 35045 | Disposed | 2029-12-17 | Common Stock (35045) | Direct |
| 2022-08-25 | Stock Option (Right to Buy) | $1.24 | M | 14855 | Disposed | 2029-12-17 | Common Stock (14855) | Direct |
Footnotes
F1: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.45 to $23.05.The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.84 to $23.42.The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: 25% of the shares subject to the option vested on October 7, 2020 and 1/48th of the shares subject to the option will vest monthly thereafter.